Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma

被引:8
作者
Amaro, Adriana Agnese [1 ]
Gangemi, Rosaria [1 ]
Emionite, Laura [1 ]
Castagnola, Patrizio [1 ]
Filaci, Gilberto [1 ,2 ]
Jager, Martine. J. J. [3 ]
Tanda, Enrica Teresa [1 ]
Spagnolo, Francesco [1 ]
Mascherini, Matteo [1 ]
Pfeffer, Ulrich [1 ]
Croce, Michela [1 ]
机构
[1] IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy
[2] Univ Genoa, Ctr Excellence Biomed Res, Dept Internal Med, I-16132 Genoa, Italy
[3] Leiden Univ Med Ctr, NL-2333 ZA Leiden, Netherlands
关键词
uveal melanoma; MEK inhibitor; statins; YAP; TAZ; HIPPO PATHWAY; GROWTH; YAP; ESTABLISHMENT; EXPRESSION; RESISTANCE; MUTATIONS; MECHANISM; ARREST; BAP1;
D O I
10.3390/cancers15030886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Uveal melanoma is a rare and aggressive disease. G alpha-proteins GNAQ and GNA11 are driver mutations that activate MAP kinase and YAP/TAZ pathways. BAP1 loss and monosomy of chromosome 3 are present in patients with high risk of metastasis. MEK-inhibitors do not significantly block UM progression. Combinations of the MEK inhibitor trametinib and different classes of drugs targeting YAP/TAZ were used to overcome resistance. Combination of trametinib and cerivastatin were synergistic in vitro and in vivo in BAP1 mutated and chromosome 3 monosomic uveal melanoma cell lines. Background: Metastatic uveal melanoma (MUM) is a highly aggressive, therapy-resistant disease. Driver mutations in G alpha-proteins GNAQ and GNA11 activate MAP-kinase and YAP/TAZ pathways of oncogenic signalling. MAP-kinase and MEK-inhibitors do not significantly block MUM progression, likely due to persisting YAP/TAZ signalling. Statins inhibit YAP/TAZ activation by blocking the mevalonate pathway, geranyl-geranylation, and subcellular localisation of the Rho-GTPase. We investigated drugs that affect the YAP/TAZ pathway, valproic acid, verteporfin and statins, in combination with MEK-inhibitor trametinib. Methods: We established IC50 values of the individual drugs and monitored the effects of their combinations in terms of proliferation. We selected trametinib and cerivastatin for evaluation of cell cycle and apoptosis. Synergism was detected using isobologram and Chou-Talalay analyses. The most synergistic combination was tested in vivo. Results: Synergistic concentrations of trametinib and cerivastatin induced a massive arrest of proliferation and cell cycle and enhanced apoptosis, particularly in the monosomic, BAP1-mutated UPMM3 cell line. The combined treatment reduced ERK and AKT phosphorylation, increased the inactive, cytoplasmatic form of YAP and significantly impaired the growth of UM cells with monosomy of chromosome 3 in NSG mice. Conclusion: Statins can potentiate the efficacy of MEK inhibitors in the therapy of UM.
引用
收藏
页数:18
相关论文
共 81 条
[1]   Cerivastatin for lowering lipids [J].
Adams, Stephen P. ;
Tiellet, Nicholas ;
Alaeiilkhchi, Nima ;
Wright, James M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (01)
[2]   Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity [J].
Amaro, Adriana ;
Mirisola, Valentina ;
Angelini, Giovanna ;
Musso, Alessandra ;
Tosetti, Francesca ;
Esposito, Alessia I. ;
Perri, Patrizia ;
Lanza, Francesco ;
Nasciuti, Francesca ;
Mosci, Carlo ;
Puzone, Roberto ;
Salvi, Sandra ;
Truini, Mauro ;
Poggi, Alessandro ;
Pfeffer, Ulrich .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) :3353-3365
[3]   Clinical perspectives of statin-induced rhabdomyolysis [J].
Antons, KA ;
Williams, CD ;
Baker, SK ;
Phillips, PS .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (05) :400-409
[4]   Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression [J].
Bakhoum, Mathieu F. ;
Francis, Jasmine H. ;
Agustinus, Albert ;
Earlie, Ethan M. ;
Di Bona, Melody ;
Abramson, David H. ;
Duran, Mercedes ;
Masilionis, Ignas ;
Molina, Elsa ;
Shoushtari, Alexander N. ;
Goldbaum, Michael H. ;
Mischel, Paul S. ;
Bakhoum, Samuel F. ;
Laughney, Ashley M. .
NATURE COMMUNICATIONS, 2021, 12 (01)
[5]   Membrane-Associated Transporter Protein (MATP) Regulates Melanosomal pH and Influences Tyrosinase Activity [J].
Bin, Bum-Ho ;
Bhin, Jinhyuk ;
Yang, Seung Ha ;
Shin, Misun ;
Nam, Yeon-Ju ;
Choi, Dong-Hwa ;
Shin, Dong Wook ;
Lee, Ai-Young ;
Hwang, Daehee ;
Cho, Eun-Gyung ;
Lee, Tae Ryong .
PLOS ONE, 2015, 10 (06)
[6]   Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin [J].
Brouwer, Niels J. ;
Konstantinou, Eleni K. ;
Gragoudas, Evangelos S. ;
Marinkovic, Marina ;
Luyten, Gregorius P. M. ;
Kim, Ivana K. ;
Jager, Martine J. ;
Vavvas, Demetrios G. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (04)
[7]   Status of RASSF1A in Uveal Melanocytes and Melanoma Cells [J].
Calipel, Armelle ;
Abonnet, Veronique ;
Nicole, Olivier ;
Mascarelli, Frederic ;
Coupland, Sarah E. ;
Damato, Bertil ;
Mouriaux, Frederic .
MOLECULAR CANCER RESEARCH, 2011, 9 (09) :1187-1198
[8]   Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation [J].
Calvert, Andrea E. ;
Chalastanis, Alexandra ;
Wu, Yongfei ;
Hurley, Lisa A. ;
Kouri, Fotini M. ;
Bi, Yingtao ;
Kachman, Maureen ;
May, Jasmine L. ;
Bartom, Elizabeth ;
Hua, Youjia ;
Mishra, Rama K. ;
Schiltz, Gary E. ;
Dubrovskyi, Oleksii ;
Mazar, Andrew P. ;
Peter, Marcus E. ;
Zheng, Hongwu ;
James, C. David ;
Burant, Charles F. ;
Chandel, Navdeep S. ;
Davuluri, Ramana V. ;
Horbinski, Craig ;
Stegh, Alexander H. .
CELL REPORTS, 2017, 19 (09) :1858-1873
[9]   Expression of MAGE genes in ocular melanoma cell lines [J].
Chen, PW ;
Murray, TG ;
Salgaller, ML ;
Ksander, BR .
JOURNAL OF IMMUNOTHERAPY, 1997, 20 (04) :265-275
[10]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55